Detection of nasopharyngeal carcinoma in Morocco (North Africa) using a multiplex methylation-specific PCR biomarker assay

Clinical Epigenetics

Volumn 7, Issue 1, 2015, Pages

  Nawaz, Imran ^a,b   Moumad, Khalid ^c,d   Martorelli, Debora ^e   Ennaji, Moulay Mustapha ^f   Zhou, Xiaoying ^a,g   Zhang, Zhe ^g   Dolcetti, Riccardo ^e   Khyatti, Meriem ^d   Ernberg, Ingemar ^a   Hu, Li Fu ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF BALOCHISTAN   (Pakistan)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d Institut Pasteur du Maroc   (Morocco)

^e CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^f HASSAN II UNIVERSITY OF CASABLANCA   (Morocco)

^g FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Biomarker; Bisulfite conversion; DNA methylation; Early diagnosis; MMSP; Morocco; NPC; Screening; TSGs

Indexed keywords

BIOLOGICAL MARKER; DNA; EPSTEIN BARR VIRUS ANTIGEN 1; LATENT MEMBRANE PROTEIN 1;

ADULT; ARTICLE; BIOASSAY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CHINA; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DNA DETERMINATION; EBNA1 GENE; EPSTEIN BARR VIRUS; ETHNICITY; FEMALE; GENETIC SCREENING; GEOGRAPHIC DISTRIBUTION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; ITALY; ITGA9 GENE; MAJOR CLINICAL STUDY; MALE; MARKER GENE; MOROCCO; MULTIPLEX METHYLATION SPECIFIC POLYMERASE CHAIN REACTION; MULTIPLEX POLYMERASE CHAIN REACTION; NASAL BIOPSY; NASOPHARYNX CARCINOMA; P16 GENE; PREVALENCE; PRIORITY JOURNAL; RASSF1A GENE; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR GENE;

HUMAN HERPESVIRUS 4;

EID: 84939793486     PISSN: 18687075     EISSN: 18687083     Source Type: Journal    
DOI: 10.1186/s13148-015-0119-8     Document Type: Article

References (82)

1. Licitra L, Bernier J, Cvitkovic E, Grandi C, Spinazze S, Bruzzi P, et al. Cancer of the nasopharynx. Crit Rev Oncol Hematol. 2003;45(2):199–213.
2. Shanmugaratnam K, Sobin LH. The World Health Organization histological classification of tumours of the upper respiratory tract and ear. A commentary on the second edition. Cancer. 1993;71(8):2689–97.
3. Tabuchi K, Nakayama M, Nishimura B, Hayashi K, Hara A. Early detection of nasopharyngeal carcinoma. Int J Otolaryngology. 2011;2011:638058. doi:10.1155/2011/638058.
4. Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2006;15(10):1765–77. doi:10.1158/1055-9965.EPI-06-0353.
5. Armstrong RW, Kannan Kutty M, Dharmalingam SK, Ponnudurai JR. Incidence of nasopharyngeal carcinoma in Malaysia, 1968–1977. Br J Cancer. 1979;40(4):557–67.
6. Devi BC, Pisani P, Tang TS, Parkin DM. High incidence of nasopharyngeal carcinoma in native people of Sarawak, Borneo Island. Cancer Epidemiol Biomarkers. 2004;13(3):482–6.
7. Lee AW, Foo W, Mang O, Sze WM, Chappell R, Lau WH, et al. Changing epidemiology of nasopharyngeal carcinoma in Hong Kong over a 20-year period (1980–99): an encouraging reduction in both incidence and mortality. Int JCancer J. 2003;103(5):680–5. doi:10.1002/ijc.10894.
8. Chaouki N, el Gueddari B. Epidemiological descriptive approach of cancer in Morocco through the activity of the National Institute of Oncology. 1986–7. Bull Cancer. 1991;78(7):603–9.
9. Bouchbika Z, Haddad H, Benchakroun N, Eddakaoui H, Kotbi S, Megrini A, et al. Cancer incidence in Morocco: report from Casablanca registry 2005–2007. Pan African Med J. 2013;16:31. doi:10.11604/pamj.2013.16.31.2791.
10. Benider A, Sahraoui S, Acharki A, Samlali R, Kahlain A. Carcinomas of the nasopharynx in children. Analysis of 50 cases. Bull Cancer. 1995;82(2):155–61.
11. Ellouz R, Cammoun M, Attia RB, Bahi J. Nasopharyngeal carcinoma in children and adolescents in Tunisia: clinical aspects and the paraneoplastic syndrome. IARC Sci Publ. 1978;20:115–29.
12. Chow KC, Ma J, Lin LS, Chi KH, Yen SH, Liu SM, et al. Serum responses to the combination of Epstein-Barr virus antigens from both latent and acute phases in nasopharyngeal carcinoma: complementary test of EBNA-1 with EA-D. Cancer Epidemiol Biomarkers Prev. 1997;6(5):363–8.
13. Huang TB. Cancer of the nasopharynx in childhood. Cancer. 1990;66(5):968–71.
14. Burt RD, Vaughan TL, McKnight B. Descriptive epidemiology and survival analysis of nasopharyngeal carcinoma in the United States. Int J Cancer. 1992;52(4):549–56.
15. Yu MC, Yuan JM. Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol. 2002;12(6):421–9.
16. Jia WH, Luo XY, Feng BJ, Ruan HL, Bei JX, Liu WS, et al. Traditional Cantonese diet and nasopharyngeal carcinoma risk: a large-scale case–control study in Guangdong China. BMC cancer. 2010;10:446. doi:10.1186/1471-2407-10-446.
17. Yu MC, Mo CC, Chong WX, Yeh FS, Henderson BE. Preserved foods and nasopharyngeal carcinoma: a case–control study in Guangxi China. Cancer Res. 1988;48(7):1954–9.
18. Yuan JM, Wang XL, Xiang YB, Gao YT, Ross RK, Yu MC. Preserved foods in relation to risk of nasopharyngeal carcinoma in Shanghai, China. Int J Cancer. 2000;85(3):358–63.
19. Nguyen-Van D, Ernberg I, Phan-Thi Phi P, Tran-Thi C, Hu L. Epstein-Barr virus genetic variation in Vietnamese patients with nasopharyngeal carcinoma: full-length analysis of LMP1. Virus Genes. 2008;37(2):273–81. doi:10.1007/s11262-008-0262-9.
20. Niedobitek G. Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. Molecular Pathology. 2000;53(5):248–54.
21. Ayadi W, Khabir A, Hadhri-Guiga B, Fki L, Toumi N, Siala W, et al. North African and Southeast Asian nasopharyngeal carcinomas: between the resemblance and the dissemblance. Bull Cancer. 2010;97(4):475–82. doi:10.1684/bdc.2010.1090.
22. Wei WI, Kwong DL. Current management strategy of nasopharyngeal carcinoma. Clinical Exp Otorhinolaryngology. 2010;3(1):1–12. doi:10.3342/ceo.2010.3.1.1.
23. Agulnik M, Siu LL. State-of-the-art management of nasopharyngeal carcinoma: current and future directions. Br J Cancer. 2005;92(5):799–806. doi:10.1038/sj.bjc.6602449.
24. Yip TT, Ngan RK, Fong AH, Law SC. Application of circulating plasma/serum EBV DNA in the clinical management of nasopharyngeal carcinoma. Oral Oncol. 2014;50(6):527–38. doi:10.1016/j.oraloncology.2013.12.011.
25. Chi KH, Chang YC, Guo WY, Leung MJ, Shiau CY, Chen SY, et al. A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys. 2002;52(5):1238–44.
26. Loyo M, Brait M, Kim MS, Ostrow KL, Jie CC, Chuang AY, et al. A survey of methylated candidate tumor suppressor genes in nasopharyngeal carcinoma. Int J Cancer. 2011;128(6):1393–403. doi:10.1002/ijc.25443.
27. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz Jr LA, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546–58. doi:10.1126/science.1235122.
28. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet. 2006;7(1):21–33. doi:10.1038/nrg1748.
29. Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer. 2004;4(9):707–17. doi:10.1038/nrc1432.
30. Lee SM, Park JY, Kim DS. Wif1 hypermethylation as unfavorable prognosis of non-small cell lung cancers with EGFR mutation. Mol Cells. 2013;36(1):69–73. doi:10.1007/s10059-013-0060-7.
31. Kaneda A, Matsusaka K, Aburatani H, Fukayama M. Epstein-Barr virus infection as an epigenetic driver of tumorigenesis. Cancer Res. 2012;72(14):3445–50. doi:10.1158/0008-5472.CAN-11-3919.
32. Lo KW, To KF, Huang DP. Focus on nasopharyngeal carcinoma. Cancer Cell. 2004;5(5):423–8.
33. Tsao SW, Yip YL, Tsang CM, Pang PS, Lau VM, Zhang G, et al. Etiological factors of nasopharyngeal carcinoma. Oral Oncol. 2014;50(5):330–8. doi:10.1016/j.oraloncology.2014.02.006.
34. Li LL, Shu XS, Wang ZH, Cao Y, Tao Q. Epigenetic disruption of cell signaling in nasopharyngeal carcinoma. Chin J Cancer. 2011;30(4):231–9.
35. Tsao SW, Tsang CM, Pang PS, Zhang G, Chen H, Lo KW. The biology of EBV infection in human epithelial cells. Semin Cancer Biol. 2012;22(2):137–43.
36. Lo KW, Huang DP. Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin Cancer Biol. 2002;12(6):451–62.
37. Flower K, Thomas D, Heather J, Ramasubramanyan S, Jones S, Sinclair AJ. Epigenetic control of viral life-cycle by a DNA-methylation dependent transcription factor. PLoS One. 2011;6(10):e25922. doi:10.1371/journal.pone.0025922.
38. Kwok WK, Pang JC, Lo KW, Ng HK. Role of the RARRES1 gene in nasopharyngeal carcinoma. Cancer Genet Cytogenet. 2009;194(1):58–64. doi:10.1016/j.cancergencyto.2009.06.005.
39. Tian F, Yip SP, Kwong DL, Lin Z, Yang Z, Wu VW. Promoter hypermethylation of tumor suppressor genes in serum as potential biomarker for the diagnosis of nasopharyngeal carcinoma. Cancer Epidemiol. 2013;37(5):708–13. doi:10.1016/j.canep.2013.05.012.
40. Takacs M, Segesdi J, Banati F, Koroknai A, Wolf H, Niller HH, et al. The importance of epigenetic alterations in the development of Epstein-Barr virus-related lymphomas. Mediterr J Hematol Infect Dis. 2009;1(2):e2009012. doi:10.4084/MJHID.2009.012.
41. Seo SY, Kim EO, Jang KL. Epstein-Barr virus latent membrane protein 1 suppresses the growth-inhibitory effect of retinoic acid by inhibiting retinoic acid receptor-beta2 expression via DNA methylation. Cancer Lett. 2008;270(1):66–76. doi:10.1016/j.canlet.2008.04.043.
42. Lung ML, Cheung AK, Ko JM, Lung HL, Cheng Y, Dai W. The interplay of host genetic factors and Epstein-Barr virus in the development of nasopharyngeal carcinoma. Chin J Cancer. 2014;33(11):556–68. doi:10.5732/cjc.014.10170.
43. Saito M, Nishikawa J, Okada T, Morishige A, Sakai K, Nakamura M, et al. Role of DNA methylation in the development of Epstein-Barr virus-associated gastric carcinoma. J Med Virol. 2013;85(1):121–7. doi:10.1002/jmv.23405.
44. Zhao J, Liang Q, Cheung KF, Kang W, Lung RW, Tong JH, et al. Genome-wide identification of Epstein-Barr virus-driven promoter methylation profiles of human genes in gastric cancer cells. Cancer. 2013;119(2):304–12. doi:10.1002/cncr.27724.
45. Matsusaka K, Kaneda A, Nagae G, Ushiku T, Kikuchi Y, Hino R, et al. Classification of Epstein-Barr virus-positive gastric cancers by definition of DNA methylation epigenotypes. Cancer Res. 2011;71(23):7187–97. doi:10.1158/0008-5472.CAN-11-1349.
46. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93(18):9821–6.
47. Hutajulu SH, Indrasari SR, Indrawati LP, Harijadi A, Duin S, Haryana SM, et al. Epigenetic markers for early detection of nasopharyngeal carcinoma in a high risk population. Mol Cancer. 2011;10:48. doi:10.1186/1476-4598-10-48.
48. Zhang Z, Sun D, Hutajulu SH, Nawaz I, Van Nguyen D, Huang G, et al. Development of a non-invasive method, multiplex methylation specific PCR (MMSP), for early diagnosis of nasopharyngeal carcinoma. PLoS One. 2012;7(11):e45908. doi:10.1371/journal.pone.0045908.
49. Hu LF, Minarovits J, Cao SL, Contreras-Salazar B, Rymo L, Falk K, et al. Variable expression of latent membrane protein in nasopharyngeal carcinoma can be related to methylation status of the Epstein-Barr virus BNLF-1 5′-flanking region. J Virol. 1991;65(3):1558–67.
50. Chang YS, Tyan YS, Liu ST, Tsai MS, Pao CC. Detection of Epstein-Barr virus DNA sequences in nasopharyngeal carcinoma cells by enzymatic DNA amplification. J Clin Microbiol. 1990;28(11):2398–402.
51. Wu TC, Mann RB, Epstein JI, MacMahon E, Lee WA, Charache P, et al. Abundant expression of EBER1 small nuclear RNA in nasopharyngeal carcinoma. A morphologically distinctive target for detection of Epstein-Barr virus in formalin-fixed paraffin-embedded carcinoma specimens. Am J Pathol. 1991;138(6):1461–9.
52. Chen CL, Wen WN, Chen JY, Hsu MM, Hsu HC. Detection of Epstein-Barr virus genome in nasopharyngeal carcinoma by in situ DNA hybridization. Intervirology. 1993;36(2):91–8.
53. Pathmanathan R, Prasad U, Chandrika G, Sadler R, Flynn K, Raab-Traub N. Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus-infected neoplasia. Am J Pathol. 1995;146(6):1355–67.
54. Lee WY, Hsiao JR, Jin YT, Tsai ST. Epstein-Barr virus detection in neck metastases by in-situ hybridization in fine-needle aspiration cytologic studies: an aid for differentiating the primary site. Head Neck. 2000;22(4):336–40.
55. Tsai ST, Jin YT, Su IJ. Expression of EBER1 in primary and metastatic nasopharyngeal carcinoma tissues using in situ hybridization. A correlation with WHO histologic subtypes. Cancer. 1996;77(2):231–6. doi:10.1002/(SICI)1097-0142(19960115)77:2<231::AID-CNCR2>3.0.CO;2-P.
56. Macdonald MR, Freeman JL, Hui MF, Cheung RK, Warde P, McIvor NP, et al. Role of Epstein-Barr virus in fine-needle aspirates of metastatic neck nodes in the diagnosis of nasopharyngeal carcinoma. Head Neck. 1995;17(6):487–93.
57. Chao TY, Chow KC, Chang JY, Wang CC, Tsao TY, Harn HJ, et al. Expression of Epstein-Barr virus-encoded RNAs as a marker for metastatic undifferentiated nasopharyngeal carcinoma. Cancer. 1996;78(1):24–9. doi:10.1002/(SICI)1097-0142(19960701)78:1<24::AID-CNCR5>3.0.CO;2-H.
58. Agulnik M, Epstein JB. Nasopharyngeal carcinoma: current management, future directions and dental implications. Oral Oncol. 2008;44(7):617–27. doi:10.1016/j.oraloncology.2007.08.003.
59. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res. 2001;61(8):3225–9.
60. Fernandez AF, Rosales C, Lopez-Nieva P, Grana O, Ballestar E, Ropero S, et al. The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Res. 2009;19(3):438–51. doi:10.1101/gr.083550.108. gr.083550.108 [pii].
61. Challouf S, Ziadi S, Zaghdoudi R, Ksiaa F, Ben Gacem R, Trimeche M. Patterns of aberrant DNA hypermethylation in nasopharyngeal carcinoma in Tunisian patients. Clin Chim Acta. 2012;413(7–8):795–802. doi:10.1016/j.cca.2012.01.018.
62. Li L, Zhang Y, Fan Y, Sun K, Su X, Du Z, et al. Characterization of the nasopharyngeal carcinoma methylome identifies aberrant disruption of key signaling pathways and methylated tumor suppressor genes. Epigenomics. 2015;7(2):155–73. doi:10.2217/epi.14.79.
63. Lo KW, Chung GTY, To KF. Acquired genetic and epigenetic alterations in nasopharyngeal carcinoma. Nasopharyngeal carcinoma: keys for translational medicine and biology. USA: Springer Science + Business Media; 2013.
64. Singh P, Chen C, Pal-Ghosh S, Stepp MA, Sheppard D, Van De Water L. Loss of integrin alpha9beta1 results in defects in proliferation, causing poor re-epithelialization during cutaneous wound healing. J Invest Dermatol. 2009;129(1):217–28. doi:10.1038/jid.2008.201.
65. Lo KW, Kwong J, Hui AB, Chan SY, To KF, Chan AS, et al. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res. 2001;61(10):3877–81.
66. Wang T, Liu H, Chen Y, Liu W, Yu J, Wu G. Methylation associated inactivation of RASSF1A and its synergistic effect with activated K-Ras in nasopharyngeal carcinoma. J Exp Clin Cancer Res. 2009;28:160. doi:10.1186/1756-9966-28-160.
67. Liggett Jr WH, Sidransky D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol. 1998;16(3):1197–206.
68. Lo KW, Cheung ST, Leung SF, van Hasselt A, Tsang YS, Mak KF, et al. Hypermethylation of the p16 gene in nasopharyngeal carcinoma. Cancer Res. 1996;56(12):2721–5.
69. Ayadi W, Karray-Hakim H, Khabir A, Feki L, Charfi S, Boudawara T, et al. Aberrant methylation of p16, DLEC1, BLU and E-cadherin gene promoters in nasopharyngeal carcinoma biopsies from Tunisian patients. Anticancer Res. 2008;28(4B):2161–7.
70. Chan KH, Gu YL, Ng F, Ng PS, Seto WH, Sham JS, et al. EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma. Int J Cancer. 2003;105(5):706–9. doi:10.1002/ijc.11130.
71. Ng WT, Choi CW, Lee MC, Chan SH, Yau TK, Lee AW. Familial nasopharyngeal carcinoma in Hong Kong: epidemiology and implication in screening. Fam Cancer. 2009;8(2):103–8. doi:10.1007/s10689-008-9213-9.
72. Stebbing J, Bower M, Syed N, Smith P, Yu V, Crook T. Epigenetics: an emerging technology in the diagnosis and treatment of cancer. Pharmacogenomics. 2006;7(5):747–57. doi:10.2217/14622416.7.5.747.
73. Deng ZW, Li YYB, Sun HC, Yao TH. Infection of nasopharyngeal carcinoma cells (CNE line) with Epstein-Barr virus. Acta Biologie Experimentalis Sinica. 1981;14(1):271–4.
74. Lawrence JB, Villnave CA, Singer RH. Sensitive, high-resolution chromatin and chromosome mapping in situ: presence and orientation of two closely integrated copies of EBV in a lymphoma line. Cell. 1988;52(1):51–61.
75. Whitaker AM. The chromosomes of the Namalwa cell line. J Biol Stand. 1985;13(2):173–5.
76. Kamranvar SA, Gruhne B, Szeles A, Masucci MG. Epstein-Barr virus promotes genomic instability in Burkitt’s lymphoma. Oncogene. 2007;26(35):5115–23. doi:10.1038/sj.onc.1210324.
77. Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002;18(11):1427–31.
78. Habeshaw G, Yao QY, Bell AI, Morton D, Rickinson AB. Epstein-Barr virus nuclear antigen 1 sequences in endemic and sporadic Burkitt’s lymphoma reflect virus strains prevalent in different geographic areas. J Virol. 1999;73(2):965–75.
79. Zhang Y, Wang R, Song H, Huang G, Yi J, Zheng Y, et al. Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Lett. 2011;303(1):21–8. doi:10.1016/j.canlet.2010.12.011.
80. Sato N, Fukushima N, Maitra A, Matsubayashi H, Yeo CJ, Cameron JL, et al. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res. 2003;63(13):3735–42.
81. Xiao X, Zhao W, Tian F, Zhou X, Zhang J, Huang T, et al. Cytochrome b5 reductase 2 is a novel candidate tumor suppressor gene frequently inactivated by promoter hypermethylation in human nasopharyngeal carcinoma. Tumor Biol. 2014; 35(4):3755–3763.
82. Zhou X. The establishment of methylation profile of nasopharyngeal carcinoma [masters]. Guangxi: Guangxi Medical University; 2009.